Trial Profile

Phase 1B Study of APVO436 in Combination With Venetoclax and Azacitidine in Elderly or Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 03 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Mipletamig (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Aptevo Therapeutics

Most Recent Events

30 Mar 2023 According to Aptevo media release, data was presented at the 64th American Society of Haematology Annual Meeting and Exposition (ASH) in Orleans showed that APVO-436 in combination with venetoclax and azacitadine was observed to be generally safe and well tolerated.
12 Sep 2021 Planned End Date changed from 1 Dec 2023 to 1 Jan 2027.
12 Sep 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com